First-of-Its-Kind Phase 3 Trial Shows Pirtobrutinib Is Noninferior to Ibrutinib in Treatment-Naïve CLL - report from ASH 2025

from Medical Digest & Congress Report · host Medical Congress News

Wojciech Jurczak discusses the results from the global, randomized BRUIN CLL-313 study presented at the American Society of Hematology's 67th Annual Meeting.Video: https://medicaldigest.org/scientific-contents/interview:first-its-kind-phase-3-trial-shows-pirtobrutinib-noninferior-ibrutinib-treatment-naive-cll

Episode metadata supplied by the publisher feed · Published Dec 17, 2025

Embed this episode

Attribution link and audio player

Ready to play

First-of-Its-Kind Phase 3 Trial Shows Pirtobrutinib Is Noninferior to Ibrutinib in Treatment-Naïve CLL - report from ASH 2025

0:00 6:53

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 6 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on December 17, 2025.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!